Apr. 24 at 3:27 PM
Breaking flow in the psychedelic space just flipped risk/reward again…
Trump reportedly signs EO pushing FDA to FAST-TRACK mental health treatments, cutting review timelines from ~6–10 months down to ~1–2 months. That’s a structural change for biotech approval velocity, not just headline noise.
If this holds, you’re looking at compression of regulatory cycles = re-rating catalyst for the whole sector.
Names on watch:
$CMPS – psilocybin-based therapy for treatment-resistant depression
$ATAI – diversified psychedelic pipeline (psilocybin, ketamine, combo plays)
$DFTX – LSD-derived anxiolytic/depression angle
$GHRS – inhalable psychedelic delivery model (non-oral disruption)
This is still a high-volatility, binary-event sector — but speed of approval just got materially repriced.
When timelines collapse, multiples expand first… fundamentals follow later.
Watch volume. Watch gaps. Watch continuation, not headlines.
Curious about the full approach?👉 Check the @MeanReverter_
